---
title: "Chongqing Lummy Pharmaceutical Co.,Ltd. (300006.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300006.SZ.md"
symbol: "300006.SZ"
name: "Chongqing Lummy Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T15:12:22.409Z"
locales:
  - [en](https://longbridge.com/en/quote/300006.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300006.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300006.SZ.md)
---

# Chongqing Lummy Pharmaceutical Co.,Ltd. (300006.SZ)

## Company Overview

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. The company was founded in 1999 and is headquartered in Chongqing, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.cqlummy.com](https://www.cqlummy.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: D (0.63)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 189 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -6.57% |  |
| Net Profit YoY | -40.14% |  |
| P/B Ratio | 3.75 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6512986568.08 |  |
| Revenue | 758040012.34 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -7.55% | D |
| Profit Margin | -17.90% | D |
| Gross Margin | 55.01% | B |
| Revenue YoY | -6.57% | D |
| Net Profit YoY | -40.14% | D |
| Total Assets YoY | -1.10% | D |
| Net Assets YoY | -6.06% | D |
| Cash Flow Margin | -25.59% | E |
| OCF YoY | -6.57% | D |
| Turnover | 0.29 | D |
| Gearing Ratio | 32.65% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Chongqing Lummy Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-6.57%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-40.14%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "3.75",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "6512986568.08",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "758040012.34",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-7.55%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-17.90%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "55.01%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-6.57%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-40.14%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.10%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-6.06%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-25.59%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-6.57%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.29",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "32.65%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -45.21 | 201/215 | - | - | - |
| PB | 3.53 | 157/215 | 3.04 | 2.87 | 2.51 |
| PS (TTM) | 8.09 | 166/215 | 7.22 | 6.66 | 5.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300006.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300006.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300006.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300006.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**